Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1/2 3Phase 1 2Phase NA 1Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma 3Leukemia, Myeloid, Acute 3Leukemia 3Myelodysplastic Syndromes 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Accelerated Phase 2Anemia, Refractory, with Excess of Blasts 2Warts 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Teratoma 1Seminoma 1Recurrence 1Neutropenia 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Biphenotypic, Acute 1Infections 1Immunologic Deficiency Syndromes 1Hodgkin Disease 1Hematologic Neoplasms 1Graft vs Host Disease 1Febrile Neutropenia 1Endodermal Sinus Tumor 1Carcinoma, Embryonal 1Breast Neoplasms 1Anemia, Refractory 1Agammaglobulinemia 1

Interventions

Stem Cell Transplantation 3pertuzumab 2entrectinib 2cobimetinib 2capmatinib 2alectinib 2Vemurafenib 2Trastuzumab 2Cyclophosphamide 2trametinib 1thymoglobulin 1peginterferon alfa-2b 1orelabrutinib 1luspatercept 1kalinox 1dabrafenib 1atezolizumab 1Trimethoprim, Sulfamethoxazole Drug Combination 1Tretinoin 1Standard of Care 1Practice Guidelines as Topic 1Patient Comfort 1Palliative Care 1Melphalan 1Immunotherapy, Adoptive 1Immunoglobulins 1Imipenem 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Ferric Oxide, Saccharated 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Hematologic Neoplasms × Filgrastim × Clear all
NCT00176839 2017-12-05

Stem Cell Transplantation for Hematological Malignancies

Masonic Cancer Center, University of Minnesota

Phase 2/3 Terminated
11 enrolled 12 charts
LymphoidOther hematologic neoplasm

Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡